About Lee Hull — Founder of Kidneyhood

Lee Hull is a kidney patient.

Diagnosed with chronic kidney disease in 1998 — specifically treatment-resistant focal segmental glomerulosclerosis (FSGS) — Lee spent years trying every available pharmacological treatment without meaningful improvement. When standard treatments failed, he turned to the primary clinical literature and spent years building a systematic understanding of what actually drives CKD progression.

What he found was a consistent signal: nitrogen load from dietary protein is a primary driver of hyperfiltration and kidney damage. Very low protein diets supplemented with keto acid analogs showed clinical promise that standard treatments did not. The problem was that no integrated, clinically proven, nutritionally complete program existed to make this approach practical for patients. Lee built one.

The Stopping Kidney Disease book series — six books, 5,000+ combined reviews, #1 Amazon nephrology category for over five years — documented the research. Albutrix and Microtrix translated it into a clinically proven product that patients worldwide could actually use.

Lee's own kidney function has been stable for over 20 years using the protocol he developed. That personal outcome was the beginning. The clinical studies, the 4,910+ patients across 20+ countries, the US and EU patents, and the international program that followed are the validation.

What Lee Has Built

• The world's first clinically proven integrated kidney disease management program
• Albutrix — the only keto acid analog proven in human patients to improve eGFR and achieve therapeutic BUN levels
• US Patent 11,253,496 and EU Patent 3,799,724, with six additional provisional patents filed in 2026
• A program active in 20+ countries, serving 4,910+ patients over 8 years
• Two new clinical studies underway in 2026
• Active FDA 505(b)(2) drug approval pathway